We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
-11.96%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$154M
AUM Growth
-$169M
Cap. Flow
-$71.1M
Cap. Flow %
-46.06%
Top 10 Hldgs %
83.53%
Holding
39
New
5
Increased
3
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$2.7M
2
ANGO icon
AngioDynamics
ANGO
+$83.2K

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.5M
2
MDRX
Veradigm Inc. Common Stock
MDRX
+$6.49M
3
VTRS icon
Viatris
VTRS
+$5.99M
4
THC icon
Tenet Healthcare
THC
+$5.61M
5
ABT icon
Abbott
ABT
+$4.91M

Sector Composition

Rank Sector Weight
1 Miscellaneous 67.51%
2 Healthcare 32.49%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$64.1M 41.52%
150,000
-250,000
-63% -$111M
BDX icon
2
CALL
Becton Dickinson
BDX
$50.3B
$16.8M 10.88%
+65,000
New +$17.6M
DXCM icon
3
CALL
DexCom
DXCM
$33.2B
$9.33M 6.04%
+100,000
New +$11.3M
VTRS icon
4
Viatris
VTRS
$19.4B
$6.66M 4.31%
675,000
-575,000
-46% -$5.99M
BDX icon
5
Becton Dickinson
BDX
$50.3B
$6.46M 4.19%
25,000
+10,000
+67% +$2.7M
VTRS icon
6
CALL
Viatris
VTRS
$19.4B
$5.92M 3.83%
+600,000
New +$6.25M
MDRX
7
DELISTED
Veradigm Inc. Common Stock
MDRX
$5.72M 3.7%
435,000
-495,000
-53% -$6.49M
MCK icon
8
McKesson
MCK
$106B
$4.78M 3.1%
11,000
-3,000
-21% -$1.26M
STRM
9
DELISTED
Streamline Health Solutions
STRM
$4.77M 3.09%
328,725
– –
OEF icon
10
CALL
iShares S&P 100 ETF
OEF
$20.5B
$4.43M 2.87%
+50,000
New +$10.4M
COLL icon
11
Collegium Pharmaceutical
COLL
$766M
$4.13M 2.68%
185,000
-190,000
-51% -$4.33M
PHR icon
12
Phreesia
PHR
$679M
$4.02M 2.6%
215,000
-75,000
-26% -$2.02M
ANGO icon
13
AngioDynamics
ANGO
$628M
$3.47M 2.25%
475,000
+10,000
+2% +$83.2K
TCMD icon
14
Tactile Systems Technology
TCMD
$495M
$3.36M 2.18%
239,222
-60,778
-20% -$1.19M
MDRX
15
CALL
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.63M 1.7%
200,000
+100,000
+100% +$1.31M
ATRC icon
16
AtriCure
ATRC
$2.62B
$1.75M 1.13%
40,000
-45,000
-53% -$2.2M
SNY icon
17
Sanofi
SNY
$106B
$1.61M 1.04%
30,000
-65,000
-68% -$3.47M
THC icon
18
Tenet Healthcare
THC
$21.3B
$1.32M 0.85%
20,000
-75,000
-79% -$5.61M
SIBN icon
19
SI-BONE Inc
SIBN
$829M
$1.06M 0.69%
50,000
-150,000
-75% -$3.47M
CERS icon
20
Cerus
CERS
$522M
$1.05M 0.68%
650,000
-1,100,000
-63% -$2.29M
TEVA icon
21
CALL
Teva Pharmaceuticals
TEVA
$42.4B
$1.02M 0.66%
+100,000
New +$931K
ABT icon
22
Abbott
ABT
$187B
– –
-45,000
Closed -$4.91M
ALKS icon
23
Alkermes
ALKS
$7.73B
– –
-100,000
Closed -$3.13M
BIO icon
24
Bio-Rad Laboratories Class A
BIO
$10.3B
– –
-2,000
Closed -$758K
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$12.9B
– –
-75,000
Closed -$6.5M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2023 Portfolio in Review

As of Q3 2023, Tamarack Advisers held 39 positions worth $154M, down 52% from $324M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Tamarack Advisers withdrew a net $71.1M in Q3 2023, closing 18 positions and reducing 12 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $6.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 68% of assets, up from 59% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Tamarack Advisers added an estimated $2.7M to Becton Dickinson.

  • Tamarack Advisers added most to Becton Dickinson in Q3 2023, an estimated $2.7M increase.
  • Tamarack Advisers's biggest Q3 2023 reduction was Veradigm Inc. Common Stock, cutting an estimated $6.49M.
  • Tamarack Advisers fully exited BioMarin Pharmaceuticals in Q3 2023, selling an estimated $6.5M.
  • Tamarack Advisers's ten largest holdings make up 84% of its $154M portfolio in Q3 2023.
  • Tamarack Advisers opened 5 new positions and closed 18 in Q3 2023.
  • Tamarack Advisers's portfolio value fell 52% quarter-over-quarter to $154M.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.